United States residents only
23andMe, along with Pfizer Inc., is launching an exciting new research study aimed at helping the thousands of patients from across the U.S. who suffer from irritable bowel disease (IBD). We hope that you will share this information with your members and network.
The goal of the project is to understand genetic factors associated with IBD onset, progression, severity, and response to treatments. Participation in the study is easy and confidential. Results from this initiative may help advance the use of precision medicine in IBD, as 23andMe’s scientists explore how genetics may underlie the differences and similarities among individuals affected with IBD.
Eligible participants will submit DNA samples through an at-home saliva collection kit and provide information about their disease via online surveys conducted through their secure 23andMe accounts. Participants will receive the 23andMe Personal Genome Service® at no cost, which includes ancestry information and un-interpreted genetic data. Participants will also be asked to answer survey(s) about their experience with IBD – their diagnosis, disease progression, medications and family history and share their de-identified individual-level data with researchers.
The IBD research initiative seeks to enroll 10,000 individuals who have been diagnosed with Crohn’s disease or ulcerative colitis. More information about the research effort and how to join the project is available at www.23andMe.com/IBD.